Product Description
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Bangladesh | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Germany | Greece | Hungary | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lithuania | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: POZEN
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Acute Coronary Syndrome|Pain, Postoperative|Muscle Cancer|Bladder Cancer|Cystitis|Edema|Trismus|Acute Pain
Phase 3: Pain, Postoperative
Phase 2: Alzheimer Disease|Headache Disorders|Migraine Disorders|Bunion|Pulpitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05679453 | P4 |
Completed |
Edema|Acute Pain|Trismus |
2022-09-25 |
|
| ChiCTR2100052003 | N/A |
Not yet recruiting |
Pain, Postoperative |
2021-12-31 |
|
| ChiCTR2000039501 | N/A |
Recruiting |
Renal Colic |
2021-01-31 |
|
| ChiCTR1900026517 | N/A |
Completed |
Renal Colic |
2019-12-01 |